Key Highlights: Implications: ChrysCapital’s planned 20–25% stake in Linux Laboratories values the CNS‑focused branded‑generics company at roughly ₹2,400–3,000 crore, reflecting ...
Key Highlights: Implications: Sanofi’s three-year LOI with Tricog Health gives the AI cardiac diagnostics startup access to Sanofi’s mentorship, market reach, and potential fundi...
Key Highlights: Implications: HRV Pharma’s ₹150 crore investment strengthens its position in complex and high-value pharmaceutical segments, particularly synthetic peptides and high-potency oncology A...
Key Highlights: Implications: Novartis India’s acquisition of the Minipress and Minipres trademarks from Pfizer gives it an established cardiovascular brand in hypertension and B...
Key Highlights: Implications: Novonesis’ €600 million investment in Patalganga will expand its enzyme production capacity in India, helping the company meet demand from biofuels,...
Key Highlights: Implications: The demerger splits India Glycols into three focused companies—chemicals/industrial gases (India Glycols), spirits/biofuels (IGL Spirits), and bio‑pharma/bio‑...
Key Highlights: Implications: Cipla’s licensing deal adds a potential new HER2-targeted cancer treatment to its pipeline in India, South Africa and five other emerging markets, stren...
Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and activ...
Key Highlights: Implications: By targeting high‑value, time‑sensitive medical logistics (radioactive isotopes, organs, emergency transfers) and airport parts delivery, the SkyDrive–Air Ind...
Key Highlights: Implications: GC Biopharma’s Hunterase IV (idursulfase) has now been approved in India (CDSCO) and Taiwan (TFDA), bringing the intravenous enzyme replacement ther...